Open Payments

The Stamford Hospital

Type
Teaching hospital
Where
Stamford, CT
Medicare CCN
070006
Received
$192,860 in 113 records, 2020 ($23,735 general, $169,124 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment55$23,735
2020Research payment58$169,124

By company

CompanyRecordsAmountYears
Genentech, Inc.9$38,8232020
E.R. Squibb & Sons, L.L.C.2$19,4592020
Bayer Healthcare Pharmaceuticals Inc.8$18,7172020
Amgen Inc.5$15,6202020
AstraZeneca Pharmaceuticals LP1$14,6082020
F. Hoffmann-La Roche AG1$11,7032020
Janssen Research & Development, LLC1$10,0462020
EMD Serono, Inc.4$9,3752020
AKEBIA THERAPEUTICS INC8$9,1462020
Aesculap, Inc.8$9,0452020
KARL STORZ Endoscopy-America18$8,0902020
Incyte Corporation2$5,9412020
CSL Behring10$4,9792020
HOLOGIC INC1$3,8002020
Abbott Laboratories1$3,4022020
Tandem Diabetes Care, Inc.10$2,6502020
Celgene Corporation1$2,5002020
Stryker Corporation16$2,1612020
Boston Scientific Corporation4$1,0012020
Olympus America Inc.1$6112020
Regeneron Pharmaceuticals, Inc.1$6002020
GE HEALTHCARE1$5772020

By nature of payment

NatureRecordsAmount
Research payment58$169,124
Gift27$17,747
Compensation for services other than consulting, including serving as faculty or as a speaker at a v26$4,811
Charitable Contribution2$1,177

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-29Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-12-29Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-12-25Amgen Inc.$1,675Research paymentCash or cash equivalentNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC.2020
2020-12-17CSL Behring$82Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-12-16Celgene Corporation$2,500Research paymentCash or cash equivalentRevlimid Drug, HematologyCelgene - Connect MDS/AML2020
2020-12-10Aesculap, Inc.$2,732GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$1,649GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$1,342GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$1,340GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$1,019GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$638GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$298GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$24GiftCash or cash equivalent2020
2020-11-23Genentech, Inc.$10,340Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyPHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC2020
2020-11-18Janssen Research & Development, LLC$10,046Research paymentCash or cash equivalentA Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for 2020
2020-11-18Genentech, Inc.$921Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyPHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC2020
2020-11-16Boston Scientific Corporation$224Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTINSIGHT ATP2020
2020-11-03Olympus America Inc.$611GiftIn-kind items and servicesThunderBeat Capital Device, Energy2020
2020-10-30Bayer Healthcare Pharmaceuticals Inc.$3,262Research paymentCash or cash equivalentNon-CoveredBAY1002670 Long term Safety vs SoC2020
2020-10-30Bayer Healthcare Pharmaceuticals Inc.$3,262Research paymentCash or cash equivalentNon-CoveredBAY1002670 Long term Safety vs SoC2020
2020-10-28Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-10-28Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-10-23Genentech, Inc.$6,267Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyA PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER2020
2020-10-21Genentech, Inc.$1,244Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyPHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC2020
2020-10-14Genentech, Inc.$1,244Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyPHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC2020
2020-10-13Stryker Corporation$414Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-10-13Stryker Corporation$187Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-10-13Stryker Corporation$86Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-10-13Stryker Corporation$23Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-10-07Genentech, Inc.$4,485Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyA PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER2020
2020-10-02Bayer Healthcare Pharmaceuticals Inc.$500Research paymentCash or cash equivalentNon-CoveredBAY1002670 Long term Safety vs SoC2020
2020-09-24CSL Behring$92Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-09-16Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-09-08Boston Scientific Corporation$224Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTINSIGHT ATP2020
2020-08-21Bayer Healthcare Pharmaceuticals Inc.$3,500Research paymentCash or cash equivalentNon-CoveredBay1002670 Endometriosis Dose finding EU & US JP CN2020
2020-08-21Bayer Healthcare Pharmaceuticals Inc.$1,375Research paymentCash or cash equivalentNon-CoveredBay1002670 Endometriosis Dose finding EU & US JP CN2020
2020-08-21Amgen Inc.$925Research paymentIn-kind items and servicesNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC.2020
2020-08-21Bayer Healthcare Pharmaceuticals Inc.$550Research paymentCash or cash equivalentNon-CoveredBay1002670 Endometriosis Dose finding EU & US JP CN2020
2020-07-30CSL Behring$825Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-07-30CSL Behring$675Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-07-30CSL Behring$225Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-07-28E.R. Squibb & Sons, L.L.C.$19,199Research paymentCash or cash equivalentOPDIVO Biological, OncologyA Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC: Nivolumab as Maintenance after Induction Chemother2020
2020-07-22Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-07-06Stryker Corporation$212Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-07-06Stryker Corporation$85Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-07-06Stryker Corporation$8Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-07-06Stryker Corporation$6Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-07-02AKEBIA THERAPEUTICS INC$4,704Research paymentCash or cash equivalentPHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M2020
2020-07-01Genentech, Inc.$3,977Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncology1L MTNBC IPATASERTIB TECENTRIQ PACLITAXEL2020
2020-06-25CSL Behring$131Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-06-20Amgen Inc.$1,548Research paymentCash or cash equivalentNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC.2020
2020-06-18AKEBIA THERAPEUTICS INC$103Research paymentCash or cash equivalentPHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M2020
2020-06-11E.R. Squibb & Sons, L.L.C.$260Research paymentCash or cash equivalentSPRYCEL Drug, OncologyStudying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase: The 5-Year Prospectiv2020
2020-05-19Amgen Inc.$1,548Research paymentCash or cash equivalentNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC.2020
2020-05-18Bayer Healthcare Pharmaceuticals Inc.$4,268Research paymentCash or cash equivalentNon-CoveredBAY1002670 Long term Safety vs SoC2020
2020-05-14Regeneron Pharmaceuticals, Inc.$600Charitable ContributionCash or cash equivalent2020
2020-05-14AKEBIA THERAPEUTICS INC$217Research paymentCash or cash equivalentPHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M2020
2020-05-01Stryker Corporation$355Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-05-01Stryker Corporation$116Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-05-01Stryker Corporation$21Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-05-01Stryker Corporation$12Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-04-27Bayer Healthcare Pharmaceuticals Inc.$2,000Research paymentCash or cash equivalentNon-CoveredBAY1002670 Long term Safety vs SoC2020
2020-04-27CSL Behring$498Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-04-22Incyte Corporation$95Research paymentCash or cash equivalentEvaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S2020
2020-04-09AKEBIA THERAPEUTICS INC$834Research paymentCash or cash equivalentPHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M2020
2020-04-09AKEBIA THERAPEUTICS INC$171Research paymentCash or cash equivalentPHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE C2020
2020-04-08Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-04-08Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-04-06Boston Scientific Corporation$493Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTINSIGHT ATP2020
2020-03-09HOLOGIC INC$3,800Research paymentCash or cash equivalentPaddle Device, Breast and Skeletal HealthCase Collection2020
2020-03-06Genentech, Inc.$9,421Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncology1L MTNBC IPATASERTIB TECENTRIQ PACLITAXEL2020
2020-03-03Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-03-02Genentech, Inc.$921Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyPHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC2020
2020-02-25AKEBIA THERAPEUTICS INC$223Research paymentCash or cash equivalentPHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M2020
2020-02-21Amgen Inc.$9,924Research paymentCash or cash equivalentNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC.2020
2020-02-18Boston Scientific Corporation$60Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTINSIGHT ATP2020
2020-02-10EMD Serono, Inc.$5,750Research paymentCash or cash equivalentBavencio Drug, OncologyStudy of Avelumab + M6620 + Carboplatin in Poly (Adenosine diphosphate ribose [ADP]-ribose) polymerase inhibitor (PARPi)2020
2020-02-10EMD Serono, Inc.$2,850Research paymentCash or cash equivalentBavencio Drug, OncologyStudy of Avelumab + M6620 + Carboplatin in Poly (Adenosine diphosphate ribose [ADP]-ribose) polymerase inhibitor (PARPi)2020
2020-02-10EMD Serono, Inc.$550Research paymentCash or cash equivalentBavencio Drug, OncologyStudy of Avelumab + M6620 + Carboplatin in Poly (Adenosine diphosphate ribose [ADP]-ribose) polymerase inhibitor (PARPi)2020
2020-02-10EMD Serono, Inc.$225Research paymentCash or cash equivalentBavencio Drug, OncologyStudy of Avelumab + M6620 + Carboplatin in Poly (Adenosine diphosphate ribose [ADP]-ribose) polymerase inhibitor (PARPi)2020
2020-02-05AstraZeneca Pharmaceuticals LP$14,608Research paymentCash or cash equivalentIMFINZI Drug, OncologyA Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and L2020
2020-02-04CSL Behring$2,000Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-02-04CSL Behring$225Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-02-04CSL Behring$225Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-02-03AKEBIA THERAPEUTICS INC$742Research paymentCash or cash equivalentPHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M2020
2020-01-31GE HEALTHCARE$577Charitable ContributionCash or cash equivalent2020
2020-01-22Incyte Corporation$5,845Research paymentCash or cash equivalentEvaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S2020
2020-01-22Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-01-15Abbott Laboratories$3,402Research paymentCash or cash equivalentCardioMEMS HF System Device, Cardiac Arrhythmias and Heart FailureCardioMEMS HF System Post Approval Study2020
2020-01-14Stryker Corporation$418Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-01-14Stryker Corporation$152Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-01-14Stryker Corporation$43Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-01-14Stryker Corporation$15Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2020
2020-01-13KARL STORZ Endoscopy-America$1,050GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$736GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$716GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$696GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$683GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$527GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$465GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$447GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$439GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$436GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$371GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$322GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$281GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$268GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$214GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$200GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$138GiftIn-kind items and services2020
2020-01-13KARL STORZ Endoscopy-America$91GiftIn-kind items and services2020
2020-01-02F. Hoffmann-La Roche AG$11,703Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyALL COMERS SSF2020
2020-01-02AKEBIA THERAPEUTICS INC$2,149Research paymentCash or cash equivalentPHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M2020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Western Connecticut Planning RegionStamford city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Stamford, CT, county Western Connecticut Planning Region, CT, state Connecticut; placed by its city name.

MeasurePlace (city or town)
Stamford, CT
County
Western Connecticut Planning Region, CT
State
Connecticut
Population B01003137,144627,0713,624,508
Population, 2020 census P1135,470-3,605,944
Median age B0100238.441.541.1
Under 18 B0100118.4%21.8%20.2%
65 and over B0100116.2%17.4%18.5%
Households B1100155,291235,3791,434,007
Foreign born B0500231.3%23.8%15.7%
Median household income B19013$111,586$128,188$95,781
Median family income B19113$126,493$161,625$122,706
Per capita income B19301$67,068$82,266$55,915
Poverty rate B1700110.1%7.5%10.0%
Unemployment rate B230254.9%5.3%5.6%
Civilian labor force B2302581,944346,5571,959,490
Mean commute (minutes) B0801328.530.826.5
Bachelor's degree or higher B1500351.7%55.5%42.5%
Housing units B2500158,655251,5301,541,822
Owner-occupied B2500348.8%66.4%66.5%
Renters B2500351.2%33.6%33.5%
Median home value B25077$624,400$652,900$366,900
Median gross rent B25064$2,276$2,110$1,488
White, not Hispanic B0300243.2%58.6%61.9%
Black B0300217.7%9.3%9.8%
Hispanic or Latino B0300228.3%20.5%18.3%
Asian B030027.3%5.4%4.7%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); Unemployment rate: 4.7% in Sep 2016 to 5.1% in Sep 2026; low 3.1%, high 11.9% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Stamford, CT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.